Abstract
Applications of large, complex carriers that deliver powerful, specific and sensitive agents (cytokines, toxins, enzymes and genetic materials) face formidable challenges. Drug targeting strategies have to traverse diverse barriers: biological (e.g., associated with drug delivery, subcellular addressing of a drug, metabolization of carriers, etc), technological (e.g., associated with production, dosing, shelf-life of a drug-carrier complexes) and socioeconomical (e.g., price, practical utility and public accessibility of a targeting strategy).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
D.Edwards, A.Ben-Jebria and R.Langer (1998) Recent advances in pulmonary drug delivery using large, porous inhaled particles. J.Appl.Physiol., 84: 379–385
M.Poznansky and R.Juliano (1984) Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol. Reviews, 36 (4): 277–336
Y.Yabe, M.Nishikawa, A.Tamada, Y.Yakakura and M.Hashida (1999) Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase. J.Pharm.Exp.Ther., 289: 176–184
M.Narita, G.Bu, J.Herz and A.Schwartz (1995) Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J. Clin. Invest., 96: 1164–1168
M. Walport (2001) Complement. New Engl.1 Med., 344: 1058–1066
M.Medof, T.Kinoshita and V.Nussenzweig (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes J. Exp. Med., 160: 1558–1578
J.Szebeni (1998) The interaction of liposomes with the complement system. Crit. Rev.Ther.Drug Carrier Systems, 15: 57–88
V.Muzykantov and J.C.Murciano (2002) Streptavidin-mediated coupling of therapeutic proteins to carrier erythrocytes. In: Erythrocyte engineering for drug delivery and targeting (M.Maniani, Ed.), Landes Bioscience-Eurekah, TX, 37–67
B.Jeong, Y.Bae, D.Lee and S.Kim (1997) Biodegradable block copolymers as injectable drug-delivery systems. Nature, 388: 860–862
A.Abuchowski, J.R.McCoy, N.C.Palczuk, T.van Es and F.F.Davis (1977) Effect of covalent attachment of polyethylene glycol on immunogenecity and circulating life of bovine liver catalase. J. Biol. Chem., 252 (11): 3852–3586
M.Scott, K.Murad, F.Koumpouras, M.Talbot and J.Eaton (1997) Chemical camouflage of antigenic determinants: Stealth erythrocytes. Proc. Natl. Acad. Sci. USA, 94: 7566–7571
J.Armstrong, H.Meiselman and T.Fisher (1997) Covalent binding of poly(ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity. Am. J. Hematol., 56: 26–28
P.Laverman, M.Carstens, O.Boerman, E.Dams, W.Oyen, N.Rooijen, F.Corstens and G.Storm (2001) Factors affecting the accelerated blood clearance of PEG-liposomes upon repeated injections. J.Pharm.Exp.Ther., 298: 607–612
CB Hansen, GY Kao, EH Moase, S Zalipsky and TM Allen (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim.Biophys.Acta. 1239: 133–44
D.Goodwin, C.Meares and M.Osen (1998) Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J. Nucl. Med., 39: 1813–1818
J.Rosenecker, W.Zhang, K.Hong, J.Lausier, P.Geppetti, S.Yoshihara, D.Papahadjopoulos and J.Nadel (1996) Increased liposome extravasation in selected tissues: effect of substance P. Proc.Nath.Acad.Sci. USA, 93: 7236–41
S.Vogel, R.Minshall, M.Pilipovic, C.Tiruppathi and A.Malik. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol., 2001; 281 (6): L1512–22
McIntosh, D.P., X.Y.Tan, P.Oh and J.E.Schnitzer (2002) Targeting endothelium and its dynamic caveoli for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc.Natl.Acad.Sci.USA, 99: 1996–2001
R.Jain. Transport of molecules, particles, and cells in solid tumors (1999) Annu.Rev. Biomed.Eng. 1: 241–263
D.Sakharov and D.Rijken (1995) Superficial accumulation of plasminogen during plasma clot lysis. Circulation, 92: 1883–1890
V.Muzykantov (1998) Immunotargeting of drugs to the pulmonary endothelium as a therapeutic strategy. Pathophysiology, 5: 15–33
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Muzykantov, V.R. (2002). Biological Barriers for Drug Targeting. In: Muzykantov, V., Torchilin, V. (eds) Biomedical Aspects of Drug Targeting. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-4627-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4627-3_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5312-4
Online ISBN: 978-1-4757-4627-3
eBook Packages: Springer Book Archive